Clinical trial · Interventional
Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors
NCT07364656CI-TRIAL-00101466not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Autoantibodies Screening | — | UNRESOLVED | — |
| Breast Cancer Females | — | UNRESOLVED | — |
| Brugada Syndrome (BrS) | — | UNRESOLVED | — |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| ECG Abnormalities | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ECG | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- OTHER
- label
- breast cancer
- interventionNames
- Diagnostic Test: ECG
- type
- OTHER
- label
- metastatic brest cancer
- interventionNames
- Diagnostic Test: ECG
- type
- OTHER
- label
- colon cancer
- interventionNames
- Diagnostic Test: ECG
- type
- OTHER
- label
- metastatic colon cancer
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patients with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic * Patients already receiving first-line therapy with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic * Signed informed consent Exclusion Criteria: * Clinically significant cardiovascular diseases (atrial fibrillation, congestive heart failure, cardiomyopathies, or inherited arrhythmic syndromes) * Known autoimmune diseases or immunodeficiencies * Use of high-dose immunosuppressive drugs or other experimental treatments that could interfere with the assessment of study endpoints
References
Publications (0)
Data not yet available
No reference posted for this study.